News

New data reveals an unmet need in the management of moderate to severe psoriasis in Greek patients.

The new dose offers a more tailored and convenient option for patients with inflammatory conditions.

New RELAX trial data show Relfydess delivers rapid onset and 6-month efficacy.

We want to know: Will you be attending the symposium in Miami Beach this week?

Maximize your AAD 2025 experience with expert tips on education, networking, and navigating the exhibit hall in Orlando.

This review of the latest dermatologic studies includes insights into the efficacy of nutraceuticals in noncystic acne, the role of antimicrobial peptides in the skin barrier, and more.

The drug, a JAK inhibitor, met all primary and secondary endpoints in a phase 3 trial for adolescent CHE.

Following his presentation at Winter Clinical Miami, Del Rosso spoke to Dermatology Times about the current treatment landscape of psoriasis.

High concentrations of particulate matter can potentially lessen the exposure to UV radiation.

Start the new year with a look at top dermatology conferences, expert insights, and the latest research on pigmentary disorders, psoriasis, and antiaging treatments.

Patients saw improvement in hydration, sebum, erythema, and scarring after just 3 treatment sessions.

In his presentation at Winter Clinical Miami, Del Rosso covered a variety of topics including refractory pediatric vitiligo.

Biologic coordinators play a key role in managing insurance approvals and ensuring coverage details are confirmed quickly, often within 48 hours.

The IL-36R antagonist has demonstrated its safety and efficacy for generalized pustular psoriasis in GEMINI-1 and GEMINI-2 studies.

Answer today’s poll and read more about the validity of dermatological content being shared on TikTok.

The clinically-backed, post-procedure sunscreen is designed to enhance skin healing, reduce redness, promote hydration, and provide broad-spectrum UV protection.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of February.

Explore the top headlines of the week including innovation in scalp treatment, therapeutic updates in rosacea, and acne vulgaris insights from James Del Rosso, DO.

In case you missed it, this week we had news about awareness resources from the Skin Cancer Foundation, burn care disparities in skin of color, aesthetic insights for patients on medication-driven weight loss journeys, and more.

As newly appointed Executive Director of the Foundation, Becky Kamowitz is combining public education with clinical needs in the fight against skin cancer.

Pilot and research grants may be awarded to research on keratinocyte biology and differentiation, genetics, biology of skin inflammation, itch, or other ichthyosis-related areas.

In an interview with Dermatology Times, Del Rosso shared the latest in the treatment landscape for patients with Darier disease.

Learn more about the in-depth topics covered in the January 2025 print issue of Dermatology Times.

A recent study found standard burn assessment tools often fail to accurately evaluate injuries in darker skin tones, leading to misdiagnosis and delays.

Researchers found that PsA patients prioritize fatigue, sleep issues, and uncertainty, often ranking them higher than doctors do.

There are numerous ways for dermatologists to get involved in initiatives from the Skin Cancer Foundation, according to Becky Kamowitz.

Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help prevent tissue damage among patients.

This innovative approach to multimodal aesthetics care was announced at IMCAS World Congress 2025.

Dermatology Times is looking back on the top stories in dermatology from the month of January.

Del Rosso outlined new and off-label therapies for the disease that he shared in his presentation at Winter Clinical Miami.